Eradication of large solid tumors by gene therapy with a T-cell receptor targeting a single cancer-specific point mutation

Clinical Cancer Research

Volumn 22, Issue 11, 2016, Pages 2734-2743

  Leisegang, Matthias ^a   Engels, Boris ^b   Schreiber, Karin ^b   Yew, Poh Yin ^b   Kiyotani, Kazuma ^b   Idel, Christian ^b   Arina, Ainhoa ^b   Duraiswamy, Jaikumar ^b   Rweichselbaum, Ralph ^b   Uckert, Wolfgang ^c,d   Nakamura, Yusuke ^b   Schreiber, Hans ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF CHICAGO   (United States)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; EPITOPE; NEOEPITOPE; PROTEIN P68; RNA; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN KINASE R; PROTEIN KINASE R, MOUSE; TUMOR ANTIGEN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; EXOME; GENE SEQUENCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE; SOLID TUMOR; T LYMPHOCYTE; TUMOR ESCAPE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BYSTANDER EFFECT; C57BL MOUSE; CROSS PRESENTATION; GENE THERAPY; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; BYSTANDER EFFECT; CELL LINE, TUMOR; CROSS-PRIMING; EIF-2 KINASE; EPITOPES, T-LYMPHOCYTE; GENETIC THERAPY; IMMUNOTHERAPY, ADOPTIVE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; POINT MUTATION; RECEPTORS, ANTIGEN, T-CELL; TUMOR ESCAPE;

EID: 84971515762     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2361     Document Type: Article

References (50)

1. Bates GJ, Nicol SM, Wilson BJ, Jacobs A-MF, Bourdon J-C, Wardrop J, et al. The DEAD box protein p68: A novel transcriptional coactivator of the p53 tumour suppressor. EMBO J 2005;24:543-53.
2. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
3. Monach PA, Meredith SC, Siegel CT, Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity 1995;2:45-59.
4. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-4.
5. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A 1995;92:7976-80.
6. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996;183:725-9.
7. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, et al. Epitope landscape in breast and colorectal cancer. Cancer Res 2008;68:889-92.
8. Offringa R. Antigen choice in adoptive T-cell therapy of cancer. Curr Opin Immunol 2009;21:190-9.
9. Robbins PF, Lu Y-C, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013;19:747-52.
10. van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013;31:e439-42.
11. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
12. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515:577-81.
13. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015;125:3384-91.
14. Schietinger A, Delrow JJ, Basom RS, Blattman JN, Greenberg PD. Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 2012;335:723-7.
15. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507-17.
16. Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 2013;31:999-1008.
17. Li H. Toward better understanding of artifacts in variant calling from highcoverage samples. Bioinformatics 2014;30:2843-51.
18. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013;29:15-21.
19. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64-9.
20. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164.
21. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. NetMHC-3.0: Accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 2008;36:W509-12.
22. Engels B, Chervin AS, Sant AJ, Kranz DM, Schreiber H. Long-term persistence of CD4 but rapid disappearance of CD8 T cells expressing an MHC class I-restricted TCR of nanomolar Affinity. Mol Ther 2012;20: 652-60.
23. Schreiber K, Arina A, Engels B, Spiotto MT, Sidney J, Sette A, et al. Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res 2012;18:2526-33.
24. Dubey P, Hendrickson RC, Meredith SC, Siegel CT, Shabanowitz J, Skipper JC, et al. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med 1997;185:695-705.
25. Popovic J, Li L-P, Kloetzel PM, Leisegang M, Uckert W, Blankenstein T. The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed. Blood 2011;118:946-54.
26. Ward PL, Koeppen H, Hurteau T, Schreiber H. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med 1989;170:217-32.
27. Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007;67:3898-903.
28. Ross SR, Solter D. Glucocorticoid regulation of mouse mammary tumor virus sequences in transgenic mice. Proc Natl Acad Sci U S A 1985;82: 5880-4.
29. Arina A, Schreiber K, Binder DC, Karrison TG, Liu RB, Schreiber H. Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. J Immunol 2014;192:1286-93.
30. Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 2007;204:49-55.
31. Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, et al. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 2013;23:516-26.
32. Schietinger A, ArinaA, Liu RB, Wells S, Huang J, Engels B, et al. Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T-cell transfer. Oncoimmunology 2013;2:e26677.
33. Schreiber K, Wu TH, Kast WM, Schreiber H. Tracking the common ancestry of antigenically distinct cancer variants. Clin Cancer Res 2001;7:871s-5s.
34. Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, et al. Eradication of established tumors by CD8 T-cell adoptive immunotherapy. Immunity 2000;13:265-76.
35. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004;10:294-8.
36. Engels B, Rowley DA, Schreiber H. Targeting stroma to treat cancers. Semin Cancer Biol 2012;22:41-9.
37. Bai X-F, Liu J, Li O, Zheng P, Liu Y. Antigenic drift as a mechanismfor tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest 2003;111: 1487-96.
38. Wen FT, Thisted RA, Rowley DA, Schreiber H. A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. Oncoimmunology 2012;1:172-8.
39. Schreiber H. Cancer Immunology. In:Paul WE, editor. Fundamental Immunology, Seventh Edition. Philadelphia: Lippincott Williams & Wilkins; 2012. p. 1200-34.
40. Parker KC, Shields M, DiBrino M, Brooks A, Coligan JE. Peptide binding to MHC class I molecules: implications for antigenic peptide prediction. Immunol Res 1995;14:34-57.
41. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014; 515:572-6.
42. Chiari R, Foury F, De Plaen E, Baurain JF, Thonnard J, Coulie PG. Two antigens recognized by autologous cytolytic T lymphocytes on amelanoma result from a single point mutation in an essential housekeeping gene. Cancer Res 1999;59:5785-92.
43. Beck-Engeser GB, Monach PA, Mumberg D, Yang F, Wanderling S, Schreiber K, et al. Point mutation in essential genes with loss or mutation of the second allele: Relevance to the retention of tumor-specific antigens. J Exp Med 2001;194:285-300.
44. Karanikas V, Colau D, Baurain JF, Chiari R, Thonnard J, Gutierrez-Roelens I, et al. High frequency of cytolytic T lymphocytes directed against a tumorspecific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001;61:3718-24.
45. Tao Y, Ruan J, Yeh S-H, Lu X, Wang Y, Zhai W, et al. Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cellpopulation genetic analysis of whole-genome data. Proc Natl Acad Sci U S A 2011;108:12042-7.
46. Wortzel RD, Philipps C, Schreiber H. Multiple tumour-specific antigens expressed on a single tumour cell. Nature 1983;304:165-7.
47. Wong SBJ, Bos R, Sherman LA. Tumor-specific CD4 T cells render the tumor environment permissive for infiltration by low-avidity CD8 T cells. J Immunol 2008;180:3122-31.
48. Schietinger A, PhilipM, Liu RB, Schreiber K, Schreiber H. Bystander killing of cancer requires the cooperation of CD4() and CD8() T cells during the effector phase. J Exp Med 2010;207:2469-77.
49. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005;174:7516-23.
50. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014;124:687-95.